Clinical Scorecard: The Role of SHMT1 in Amino Acid Metabolism as a Standalone Prognostic Indicator in Laryngeal Squamous Cell Carcinoma
At a Glance
Category
Detail
Condition
Laryngeal Squamous Cell Carcinoma (LSCC)
Key Mechanisms
Amino acid metabolism reprogramming supports tumor proliferation and shapes tumor microenvironment; SHMT1 identified as a prognostic gene related to amino acid metabolism
Target Population
Patients diagnosed with LSCC, particularly those with advanced-stage disease
Care Setting
Oncology clinical settings including surgical, radiotherapy, chemotherapy, and immunotherapy contexts
Key Highlights
LSCC accounts for the second most prevalent head and neck cancer with high mortality and advanced-stage diagnosis in 60% of cases
Amino acid metabolism reprogramming is critical in tumor growth and immune suppression, making it a promising therapeutic target
A prognostic risk model based on amino acid metabolism-related genes, including SHMT1, was developed and validated to predict LSCC patient survival
Guideline-Based Recommendations
Diagnosis
Utilize transcriptomic profiling to identify differential expression of amino acid metabolism-related genes in LSCC
Incorporate prognostic risk scoring based on gene expression (e.g., SHMT1) to stratify patient risk
Management
Consider targeting amino acid metabolism pathways as adjunct therapeutic strategies
Explore immunotherapy approaches that modulate amino acid metabolism to enhance anti-tumor immune responses
Monitoring & Follow-up
Apply prognostic models to monitor patient survival probabilities at 1, 3, and 5 years
Use risk scores alongside clinical features to guide treatment decisions and follow-up intensity
Risks
High recurrence rates and treatment-associated toxicity remain challenges in LSCC management
Metabolic targeting therapies require careful evaluation for efficacy and safety in LSCC
Patient & Prescribing Data
LSCC patients with transcriptomic data available for amino acid metabolism gene expression
Prognostic risk models incorporating SHMT1 expression can inform personalized treatment planning and identify candidates for metabolic-targeted therapies
Clinical Best Practices
Integrate multi-omics data (TCGA, GEO) for comprehensive molecular profiling in LSCC
Employ bioinformatics tools (edgeR, clusterProfiler, STRING, Cytoscape) for gene expression and network analysis
Validate prognostic models externally to ensure robustness and clinical applicability
